Analyst cuts regeneron pharmaceuticals (regn) price target after sales concerns and investor lawsuit– hagens berman

San francisco, feb. 05, 2025 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) is facing mounting pressure on multiple fronts. following disappointing sales figures and ongoing legal challenges, analysts td cowen recently lowered its price target for regeneron to $1,030 from $1,230. the downward revision reflects preannounced january figures for eylea®, a key product in regeneron's portfolio, with td cowen citing increased competition in the market and significantly lowering its revenue estimates for the eylea® franchise.
REGN Ratings Summary
REGN Quant Ranking